Literature DB >> 4938431

Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa.

D B Calne, J L Reid, S D Vakil, S Rao, A Petrie, C A Pallis, J Gawler, P K Thomas, A Hilson.   

Abstract

The clinical actions of levodopa in Parkinsonism, given with and without an extracerebral decarboxylase in hibitor, L-alpha-methyldopahydrazine, were compared. Twenty-one patients were investigated in a "double-blind cross-over" study, administering levodopa in maximum tolerated dosage. L-Alpha-methyldopahydrazine failed to augment the overall therapeutic actions of levodopa but it consistently alleviated nausea. It is concluded that L-alpha-methyldopahydrazine will prove useful in the management of some Parkinsonian patients who have difficulty in taking levodopa alone.

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4938431      PMCID： PMC1798919          DOI： 10.1136/bmj.3.5777.729

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


  13 in total

1.  Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase.

Authors:  G Bartholini; W P Burkard; A Pletscher
Journal:  Nature       Date:  1967-08-19       Impact factor: 49.962

2.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

3.  Blocking the negative effects of pyridoxine on patients receiving levodopa.

Authors:  G C Cotzias; P S Papavasiliou
Journal:  JAMA       Date:  1971-03-01       Impact factor: 56.272

4.  False rise in serum uric acid after L-dopa.

Authors:  M J Cawein; J Hewins
Journal:  N Engl J Med       Date:  1969-12-25       Impact factor: 91.245

5.  Pyridoxine reversal of L-dopa effects in Parkinsonism.

Authors:  R C Duvoisin; M D Yahr; L D Coté
Journal:  Trans Am Neurol Assoc       Date:  1969

6.  Treatment of Parkinson's syndrome with L-dopa. A double blind study.

Authors:  C Fehling
Journal:  Acta Neurol Scand       Date:  1966       Impact factor: 3.209

7.  Interaction of DOPA decarboxylase inhibitors with the effect of alpha-methyldopa on blood pressure and tissue monoamines in rats.

Authors:  M Henning
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1969

8.  Plasma DOPA response to levodopa administration in man: effects of a peripheral decarboxylase inhibitor.

Authors:  D L Dunner; H K Brodie; F K Goodwin
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

9.  L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.

Authors:  M D Muenter; G M Tyce
Journal:  Mayo Clin Proc       Date:  1971-04       Impact factor: 7.616

10.  Prevention or reversal of levodopa-induced cardiac arrhythmias by decarboxylase inhibitors.

Authors:  L C Parks; A M Watanabe; I J Kopin
Journal:  Lancet       Date:  1970-11-14       Impact factor: 79.321
View more
  22 in total

1.  Polypharmacy in Parkinson's disease: risks and benefits with little evidence.

Authors:  I Csoti; H Herbst; P Urban; D Woitalla; U Wüllner
Journal:  J Neural Transm (Vienna)       Date:  2019-06-20       Impact factor: 3.575

2.  Plasma dopa concentrations after different preparations of levodopa in normal subjects.

Authors:  J G Morris; R L Parsons; J R Trounce; M J Groves
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

3.  Objective outcome criteria in trials of anti-parkinsonian therapy in the elderly: sensitivity, specificity and reliability of measures of brady- and hypo-kinesia.

Authors:  S G Bowes; P K Clark; A Charlett; C J O'Neill; A L Leeman; C Weller; P W Nicholson; A A Deshmukh; S M Dobbs; R J Dobbs
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

4.  Treatment of the on-off syndrome in Parkinsonism with low dose bromocriptine in combination with levodopa.

Authors:  D N Bateman; A Coxon; N J Legg; J L Reid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-12       Impact factor: 10.154

Review 5.  Parkinson's disease and levodopa. A five-year follow-up and review.

Authors:  C H Markham; L J Treciokas; S G Diamond
Journal:  West J Med       Date:  1974-09

Review 6.  Augmenting the action of levodopa.

Authors:  S K Rao; S D Vakil; D B Calne; A Hilson
Journal:  Postgrad Med J       Date:  1972-11       Impact factor: 2.401

7.  Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.

Authors:  J D Parkes; R C Baxter; C D Marsden; J E Rees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-04       Impact factor: 10.154

Review 8.  The pharmacology of Parkinson's disease: basic aspects and recent advances.

Authors:  M Da Prada; H H Keller; L Pieri; R Kettler; W E Haefely
Journal:  Experientia       Date:  1984-11-15

Review 9.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

10.  "On-off" phenomena related to high plasma levodopa.

Authors:  L E Claveria; D B Calne; J G Allen
Journal:  Br Med J       Date:  1973-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.